NotíciasBenzingaKodiak Sciences Says Phase 3 DAYBREAK Study Met Primary Endpoints With Zenkuda (Tarcocimab Tedromer) And Tabirafusp-ted (KSI-501) Showing Non-inferiority In Vision Gains For Wet Age-related Macular Degeneration Vs. Aflibercept At Year One Kodiak Sciences Says Phase 3 DAYBREAK Study Met Primary Endpoints With Zenkuda (Tarcocimab Tedromer) And Tabirafusp-ted (KSI-501) Showing Non-inferiority In Vision Gains For Wet Age-related Macular Degeneration Vs. Aflibercept At Year One Benzinga 2026.09.28 10:34 (GMT+0) Abrir em Benzinga Outras notícias Raymond James inicia cobertura da Encompass Health com recomendação de compra forte Raymond James inicia cobertura da Acadia Healthcare com recomendação de outperform Raymond James inicia cobertura da Community Health com recomendação de underperform Brookline inicia cobertura de Revolution Medicines com recomendação de compra 3 desbloqueios de tokens para observar nesta semana Cantor Fitzgerald reitera classificação acima da média para Verastem antes de divulgação de dados
